Ad is loading...
MENU

PPBT Stock Purple Biotech (PPBT, $3.21) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 31, 2024

A.I.dvisor
at Tickeron.com
Loading...
PPBT - Purple Biotech Ltd
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $3.21
Daily change: -$0.09 (-2.73%)
Daily volume: 16K
Industry: Biotechnology
This is a Bearish indicator signaling PPBT's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 44 similar cases where PPBT's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

Momentum Indicator for PPBT turns negative, indicating new downward trend

PPBT saw its Momentum Indicator move below the 0 level on October 25, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PPBT entered a downward trend on November 11, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for PPBT just turned positive on November 12, 2024. Looking at past instances where PPBT's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

PPBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.134) is normal, around the industry mean (14.849). P/E Ratio (0.000) is within average values for comparable stocks, (95.928). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). PPBT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (211.128).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PPBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PPBT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of pharmaceutical drug discovery and development services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
4 Oppenheimer Street
Phone
+972 39333121
Employees
13
Web
https://www.purple-biotech.com